Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for AXSM, APPS and U: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Tuesday, 12 July 2022 11:30 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / July 12, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AXSM Shareholders Click Here: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=29752&wire=1
APPS Shareholders Click Here: https://www.zlk.com/pslra-1/digital-turbine-inc-loss-submission-form?prid=29752&wire=1
U Shareholders Click Here: https://www.zlk.com/pslra-1/unity-software-loss-submission-form?prid=29752&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Tuesday, July 12, 2022, Press release picture

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

AXSM Lawsuit on behalf of: investors who purchased December 30, 2019 - April 22, 2022
Lead Plaintiff Deadline : July 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=29752&wire=1

According to the filed complaint, during the class period, Axsome Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Digital Turbine, Inc. (NASDAQ:APPS)

APPS Lawsuit on behalf of: investors who purchased August 9, 2021 - May 17, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/digital-turbine-inc-loss-submission-form?prid=29752&wire=1

According to the filed complaint, during the class period, Digital Turbine, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Unity Software Inc. (NYSE:U)

U Lawsuit on behalf of: investors who purchased March 5, 2021 - May 10, 2022
Lead Plaintiff Deadline : September 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unity-software-loss-submission-form?prid=29752&wire=1

According to the filed complaint, during the class period, Unity Software Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies in Unity's product platform reduced the accuracy of the Company's machine learning technology; (ii) the foregoing was likely to have a material negative impact on the Company's revenues; (iii) accordingly, Unity had overstated the Company's commercial and/or financial prospects for 2022; (iv) as a result, the Company was likely to have to reduce its fiscal 2022 guidance; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: